Rivaroxaban Impurity 145 | CAS 55435-71-7 - Request Quote
Rivaroxaban Impurity 145
| SZ CAT No: | SZ-R017222 |
| CAS No | 55435-71-7 |
| Mol.F. | C10H11ClN2O3 |
| Mol.Wt. |
242.7 |
| Inv. Status |
In Stock |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
CHNS Ratio (%) :
Usage Note:
Rivaroxaban Impurity 145 is chemically 4-(2-chloro-4-nitrophenyl)morpholine. Rivaroxaban Impurity 145 is supplied with detailed characterization data compliant with regulatory guideline. Rivaroxaban Impurity 145 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Rivaroxaban.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 55435-71-7
Purchase 55435-71-7
Order 55435-71-7
Enquire 55435-71-7
price of 55435-71-7
55435-71-7 Supplier
55435-71-7 Manufacturer
55435-71-7 Exporter
buy high quality Rivaroxaban Impurity 145
Purchase Rivaroxaban Impurity 145
Rivaroxaban Impurity 145 suppliers
Rivaroxaban Impurity 145 manufacturers
Rivaroxaban Impurity 145 price
Order Rivaroxaban Impurity 145
Enquire Rivaroxaban Impurity 145
Rivaroxaban Impurity 145 cost
Rivaroxaban Impurity 145 Supplier
Rivaroxaban Impurity 145 Distributor
Rivaroxaban Impurity 145 for Method Validation
Rivaroxaban Reference Standard
Rivaroxaban Impurity 145 for ANDA Filing
Rivaroxaban Impurity 145 for Forced Degradation Studies
Rivaroxaban Impurity 145 Identification Standards
Rivaroxaban Impurity 145 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.